To date, a growing number of EPH/ephrin-targeting therapeutic agents is in advanced preclinical development, or has even entered phase I/II clinical investigation [51,52], thus encouraging international scientific groups to further develop novel agents targeting this system in different cancer entities. This evidence concerns the gene EPHA1 and cancer.